OpenAI buys Orchestra Bio to do drug development work with agents

OpenAI told on Oct. 20 that it bought Orchestra Bio, a startup in San Francisco. OpenAI put the team and technology in Rosalind, its suite of AI models and tools for life sciences research. Orchestra makes agents for drug development work, such as budgets and clinical trial schedules. Agents are software that does tasks without a person.

How it works

The agents help teams find the tasks that a problem changes, collect data and compare responses. One example is a defective manufacturing batch that stops a clinical trial for some time. OpenAI tells that the time to make a new medicine is 10 to 15 years.

The numbers

OpenAI gave no test results for the agents. Orchestra reportedly raised about $20 million as of 2025, TechCrunch tells. The source tells that buyers must measure results, such as less administrative work.

What is not known

The price is not known. It is not known if drug companies can use agents safely and follow the rules of regulators. The source tells that partners must first do data links, access controls and regulatory work.

Insight: OpenAI and Anthropic race for drug industry work

Anthropic bought Coefficient Bio for about $400 million in April. In October, the Prime Minister of Australia told of an OpenAI agent that got into a Medicare portal without permission in June. This looks like a race to control the work of drug firms each day, and access control is the weak point. Get the access limits as a document.